Literature DB >> 8255518

Monitoring of iron requirements in renal patients on erythropoietin.

E G Anastassiades1, D Howarth, J Howarth, D Shanks, H M Waters, K Hyde, C G Geary, J A Yin, R Gokal.   

Abstract

We studied 38 patients (9 haemodialysis, 18 peritoneal dialysis, 11 advanced renal failure) over the first 12 weeks of erythropoietin therapy. In 14 iron-overloaded patients (ferritin > 500 micrograms/l the haemoglobin (+/- SEM) increased from 6.74 +/- 0.27 to 9.85 +/- 0.36 g/dl (P < 0.0001) entirely by mobilizing iron reserves (reduced from 1,220 +/- 73 to 739 +/- 111 mg, P < 0.0001). In the 24 non-overloaded patients (ferritin < 500 micrograms/l) the haemoglobin rose similarly from 7.04 +/- 0.18 to 10.70 +/- 0.36 g/dl (P < 0.0001), partly from iron reserves (depleted from 200 +/- 74 to -44 +/- 77 mg, P = 0.016) and partly from oral iron supplements (305 +/- 110 mg). In the overloaded patients the ferritin declined from 1057 micrograms/l (geometric mean, range 504-3699) to 317 micrograms/l (42-1505, P < 0.0001). In the non-overloaded patients it declined from 82 micrograms/l (8-461) to 45 micrograms/l (5-379, P = 0.016). The transferrin saturation (TS) in the overloaded patients appeared to decline from 38.3 +/- 7.2% to 24.0 +/- 3.7% but this was not statistically significant. In the non-overloaded the TS was unchanged (23.3 +/- 2.4 before and 28.1 +/- 3.6% after treatment). Considering all 38 patients together, the haemoglobin correlated negatively with the ferritin (r = 0.3731, P < 0.001) but not with the TS. The TS correlated with the serum ferritin initially (r = 0.75, P < 0.001) but not after the first 4 weeks.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255518

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Plasma erythropoietin level and iron reserves in haemodialysis patients with and without acquired cystic kidney disease.

Authors:  M Majdan; A Ksiazek; M Kozioł; D Spasiewicz
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

2.  The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in haemodialysis patients.

Authors:  H Z Tonbul; H Kaya; N Y Selçuk; S B Tekin; A San; F Akçay; E Akarsu
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 3.  Safety aspects of parenteral iron in patients with end-stage renal disease.

Authors:  G Sunder-Plassmann; W H Hörl
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

4.  Changes of endogenous erythropoietin level and iron status during a 30-month hemodialysis treatment of a group of patients.

Authors:  M Majdan; A Ksiazek; A Bednarek-Skublewska; D Spasiewicz
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

5.  Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study.

Authors:  Guy Rostoker; Mireille Griuncelli; Christelle Loridon; Théophile Magna; Gabrielle Machado; Gilles Drahi; Hervé Dahan; Philippe Janklewicz; Yves Cohen
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

Review 6.  Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century.

Authors:  Guy Rostoker; Nosratola D Vaziri; Steven Fishbane
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.